Science Explorer Back to mapMap
Discussion

Sigma-Tau Pharmaceuticals (United States)

Research works
16
▲ 21% vs 2018-21
Citations
869
53.8 per fractional work
Top-10% rate
11.8%
all institutions 10.0%
Open access
27%
world 40%
International
42%
world 18%

Not ranked overall: Sigma-Tau Pharmaceuticals (United States) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Sigma-Tau Pharmaceuticals (United States) work in?

In all years, 64% of research at Sigma-Tau Pharmaceuticals (United States) is in Health Sciences, 32% in Life Sciences. Its largest fields are Medicine (60%), Biochemistry, Genetics and Molecular Biology (25%), Pharmacology, Toxicology and Pharmaceutics (3%). It does 2.0× the world's share of Health Sciences.

Health Sciences: 10 fractional works · 63.6% of its workMedicine: 10 fractional works · 60.0% of its workPhysiology: 2 fractional works · 11.3% of its workPediatrics, Perinatology and Child Health: 1 fractional works · 7.5% of its workPsychiatry and Mental health: 1 fractional works · 5.5% of its workPublic Health, Environmental and Occupational Health: 1 fractional works · 5.0% of its workSurgery: 1 fractional works · 4.1% of its workOncology: 1 fractional works · 4.0% of its workNephrology: 1 fractional works · 3.4% of its workPulmonary and Respiratory Medicine: 0 fractional works · 2.9% of its workCardiology and Cardiovascular Medicine: 0 fractional works · 2.2% of its workInfectious Diseases: 0 fractional works · 2.0% of its workPathology and Forensic Medicine: 0 fractional works · 1.7% of its workRadiology, Nuclear Medicine and Imaging: 0 fractional works · 1.7% of its workGenetics: 0 fractional works · 1.5% of its workEndocrinology, Diabetes and Metabolism: 0 fractional works · 1.4% of its workPharmacology: 0 fractional works · 1.4% of its workNeurology: 0 fractional works · 1.2% of its workHematology: 0 fractional works · 0.7% of its workEmergency Medicine: 0 fractional works · 0.5% of its workCritical Care and Intensive Care Medicine: 0 fractional works · 0.4% of its workGastroenterology: 0 fractional works · 0.4% of its workRheumatology: 0 fractional works · 0.4% of its workReproductive Medicine: 0 fractional works · 0.4% of its workEpidemiology: 0 fractional works · 0.2% of its workNursing: 0 fractional works · 2.0% of its workNutrition and Dietetics: 0 fractional works · 2.0% of its workHealth Professions: 0 fractional works · 1.5% of its workPharmacy: 0 fractional works · 1.1% of its workEmergency Medical Services: 0 fractional works · 0.5% of its workLife Sciences: 5 fractional works · 31.7% of its workBiochemistry, Genetics and Molecular Biology: 4 fractional works · 25.4% of its workClinical Biochemistry: 2 fractional works · 13.8% of its workMolecular Biology: 1 fractional works · 9.0% of its workCancer Research: 0 fractional works · 1.1% of its workBiochemistry: 0 fractional works · 0.7% of its workGenetics: 0 fractional works · 0.6% of its workCell Biology: 0 fractional works · 0.2% of its workPharmacology, Toxicology and Pharmaceutics: 0 fractional works · 2.5% of its workPharmaceutical Science: 0 fractional works · 1.5% of its workToxicology: 0 fractional works · 0.7% of its workPharmacology: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.1% of its workNeuroscience: 0 fractional works · 2.4% of its workCellular and Molecular Neuroscience: 0 fractional works · 2.4% of its workAgricultural and Biological Sciences: 0 fractional works · 1.4% of its workAnimal Science and Zoology: 0 fractional works · 0.7% of its workFood Science: 0 fractional works · 0.7% of its workPhysical Sciences: 1 fractional works · 4.2% of its workEnvironmental Science: 0 fractional works · 2.0% of its workHealth, Toxicology and Mutagenesis: 0 fractional works · 2.0% of its workChemistry: 0 fractional works · 0.7% of its workAnalytical Chemistry: 0 fractional works · 0.7% of its workEngineering: 0 fractional works · 0.6% of its workBiomedical Engineering: 0 fractional works · 0.4% of its workSmaller subfields together: 0 fractional works · 0.1% of its workMaterials Science: 0 fractional works · 0.4% of its workMaterials Chemistry: 0 fractional works · 0.4% of its workMathematics: 0 fractional works · 0.4% of its workStatistics and Probability: 0 fractional works · 0.4% of its workSocial Sciences: 0 fractional works · 0.6% of its workPsychology: 0 fractional works · 0.2% of its workExperimental and Cognitive Psychology: 0 fractional works · 0.2% of its workEconomics, Econometrics and Finance: 0 fractional works · 0.2% of its workSocial Sciences: 0 fractional works · 0.2% of its workALL ITS WORKSigma-TauPharmaceuticals…16fractional works, all years
Life Sciences32%Physical Sciences4%Health Sciences64%Social Sciences1%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 15 fields, with their numbers
    1. Medicine1060.0%
    2. Nursing02.0%
    3. Health Professions01.5%
    1. Biochemistry, Genetics and Molecular Biology425.4%
    2. Pharmacology, Toxicology and Pharmaceutics02.5%
    3. Neuroscience02.4%
    4. Agricultural and Biological Sciences01.4%
    1. Environmental Science02.0%
    2. Chemistry00.7%
    3. Engineering00.6%
    4. Materials Science00.4%
    5. Mathematics00.4%
    1. Psychology00.2%
    2. Economics, Econometrics and Finance00.2%
    3. Social Sciences00.2%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Who are the top researchers at Sigma-Tau Pharmaceuticals (United States)?

Ranked on the quality score, Antonino Amato lead among researchers whose main affiliation is Sigma-Tau Pharmaceuticals (United States).

  1. 1 Antonino Amato United States · #2,654,318 worldwide 2.9k citations · 70 works
All ranked researchers at Sigma-Tau Pharmaceuticals (United States)

What are the most cited papers from Sigma-Tau Pharmaceuticals (United States)?

The most cited paper from Sigma-Tau Pharmaceuticals (United States) is "Elevated Triglycerides Correlate With Progression of Diabetic Neuropathy" (Timothy D. Wiggin, Kelli A. Sullivan, Rodica Pop‐Busui et al., 2009), with 351 citations. Next come "IKZF1 plus Defines a New Minimal Residual Disease–Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia" (309) and "Pharmacokinetics of L-Carnitine" (304).

Most cited papers
#PaperReleasedCitations
1 Elevated Triglycerides Correlate With Progression of Diabetic Neuropathy Timothy D. Wiggin, Kelli A. Sullivan, Rodica Pop‐Busui et al. · Diabetes Open access May 2009 351
2 IKZF1 plus Defines a New Minimal Residual Disease–Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia Martin Stanulla et al. · Journal of Clinical Oncology Open access 2 Mar 2018 309
3 Pharmacokinetics of L-Carnitine Allan M. Evans, Gianfranco Fornasini · Clinical Pharmacokinetics 2003 304
4 Acetyl- l -Carnitine Improves Pain, Nerve Regeneration, and Vibratory Perception in Patients With Chronic Diabetic Neuropathy Anders A. F. Sima, Menotti Calvani, Munish Mehra et al. · Diabetes Care 2005 234
5 Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children’s Oncology Group Randomized Trial Pediatric Oncology Group 9404 Barbara L. Asselin, Meenakshi Devidas, Lu Chen et al. · Journal of Clinical Oncology Open access 23 Dec 2015 205
All 44 most cited papers, with filters and sorting

Which research topics does Sigma-Tau Pharmaceuticals (United States) publish most on?

By volume in 2022-now: Ovarian function and disorders, Reproductive Biology and Fertility and TGF-β signaling in diseases.

Ovarian function and dis…0Ovarian function and disorders: 0 fractional worksReproductive Biology and…0Reproductive Biology and Fertility: 0 fractional worksTGF-β signaling in disea…0TGF-β signaling in diseases: 0 fractional works
Reproductive MedicinePublic Health, Environmental and Occupational HealthMolecular Biology

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Ovarian function and disorders Reproductive Medicine 0 works
  2. 2 Reproductive Biology and Fertility Public Health, Environmental and Occupational Health 0 works
  3. 3 TGF-β signaling in diseases Molecular Biology 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available27.1%not open72.9%

World: 40% of research is openly available.

with international co-authors42.4%domestic only57.6%

World: 18% is written across borders.

How has Sigma-Tau Pharmaceuticals (United States)'s research output changed?

Output in 2022-2025 was 21% higher than in 2018-2021.

200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Sigma-Tau Pharmaceuticals (United States) as a percentage of every work published that year, 0.0000033% in 2018.

0.00010%0.00020%0.00030%Sigma-Tau Pharmaceuticals (United States)0.0000031% in 2024200020102020

Fractional works of Sigma-Tau Pharmaceuticals (United States) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Gaithersburg

All research institutions in Gaithersburg

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Sigma-Tau Pharmaceuticals (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.